Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Facial moisturizer with piroctone olamine, saccharide isomerate, and hydroxyphenyl propamidobenzoic acid for facial dermatitis
TCTR20260901001Phase 3Completed
- Sponsor
- N/A
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of piroctone in facial dermatitis, atopic dermatitis (AD) and seborrheic dermatitis (SD) (2 arms), sponsored by N/A. Primary endpoint: Investigator Global Assessment (IGA) score. Started Dec 2023; status: completed.
02
Drugs
piroctone
03
Conditions
facial dermatitisatopic dermatitis (AD)seborrheic dermatitis (SD)
Beyond the preview
Go deeper on TCTR20260901001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260901001.